Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Lonsurf-Bevacizumab Snags US Approval for Colorectal Cancer: Taiho
August 4, 2023
- Opdivo Tops Japan Sales Ranking for 19 Months on End: Encise
August 4, 2023
- Eisai Sees Positive Shift in US Market for Leqembi after Full Approval: Exec
August 3, 2023
- Sumitomo to Focus on 3 Core Products in North America to Overcome Latuda Patent Cliff: President
August 3, 2023
- Mitsubishi Tanabe’s Q1 Sales Up 3.8% on Back of Bullish Oral Radicava Sales in US
August 3, 2023
- Pfizer’s Bivalent COVID Vaccines Approved for Primary Series in Japan
August 3, 2023
- Eligibility Age of Moderna COVID Vaccine Lowered to 6 and Older
August 3, 2023
- Moderna Japan’s XBB-Based COVID Jab Actually Filed for Age 6 and Up
August 3, 2023
- Japan OKs 1st Homemade COVID Jab, but No Supply Planned; Daiichi to Pursue XBB.1 Update
August 3, 2023
- Eisai’s Q1 Operating Profit Jumps on Lenvima Growth, Lower Aduhelm Cost
August 3, 2023
- Japan Greenlights Shionogi’s Stable Supply Plan for 2 Cephalosporin Antibiotics
August 2, 2023
- Mitsubishi Tanabe Drops Once-Daily Oral Edaravone Regimen for ALS
August 2, 2023
- Astellas’ Q1 Sales Skid on Lexiscan Generic Erosion, but Full-Year Growth Expected with Hot Flash Med
August 2, 2023
- Kaken’s Burn Eschar Remover NexoBrid Now Available in Japan
August 2, 2023
- Lonsurf-Bevacizumab Combo Approved in EU for Colorectal Cancer: Taiho
August 2, 2023
- Astellas’ Zolbetuximab Accepted for Review in China for CLDN18.2 Gastric Cancer
August 2, 2023
- AbbVie Merges Allergan in Japan after Global Acquisition
August 2, 2023
- Japan Approves Gilead’s HIV Med Sunlenca, Listing Set for Aug. 9
August 2, 2023
- Astellas to Cut 500 More Jobs in Buyout Targeting Commercial Unit
August 2, 2023
- Sumitomo/Otsuka’s Blockbuster Hopeful Ulotaront Misses Primary Goals in PIII Schizophrenia Studies
August 1, 2023
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…